Pfizer extends drug development agreement with Durham-based Icagen
Local Tech Wire
The companies are exploring and developing compounds that utilize sodium ion channels.
Pfizer will commit another $5 million in funding to Icagen. The companies have already been working together for two years. The revised contract also includes formation of a joint research committee.
The sodium channels are part of electrical signals in nerve fibers.
If the partnership produces approved products, Icagen could receive as much as $359 million for achieving development, regulatory and commercialization milestones for each product. Icagen also would receive royalties.
"We have made substantial progress over the first two years of our collaboration and look forward to working with Icagen in the upcoming year in seeking to identify drug candidates from these targeted programs,” said Gillian Burgess, chief scientific officer of Pfizer’s Pain Research Unit, in a statement.
Please log in to view WRALTechWire Insider content
Please Log In to add a comment.
Best of TechWire Insider
- NC Biotech Center braces for worst as Senate slashes budget, too
- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows